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Abstract
Background: The chest pain unit (CPU) provides rapid diagnostic assessment for patients with
acute, undifferentiated chest pain, using a combination of electrocardiographic (ECG) recording,
biochemical markers and provocative cardiac testing. We aimed to identify which elements of a
CPU protocol were most diagnostically and prognostically useful.
Methods: The Northern General Hospital CPU uses 2–6 hours of serial ECG / ST segment
monitoring, CK-MB(mass) on arrival and at least two hours later, troponin T at least six hours after
worst pain and exercise treadmill testing. Data were prospectively collected over an eighteen-
month period from patients managed on the CPU. Patients discharged after CPU assessment were
invited to attend a follow-up appointment 72 hours later for ECG and troponin T measurement.
Hospital records of all patients were reviewed to identify adverse cardiac events over the
subsequent six months. Diagnostic accuracy of each test was estimated by calculating sensitivity and
specificity for: 1) acute coronary syndrome (ACS) with clinical myocardial infarction and 2) ACS
with myocyte necrosis. Prognostic value was estimated by calculating the relative risk of an adverse
cardiac event following a positive result.
Results: Of the 706 patients, 30 (4.2%) were diagnosed as ACS with myocardial infarction, 30
(4.2%) as ACS with myocyte necrosis, and 32 (4.5%) suffered an adverse cardiac event. Sensitivities
for ACS with myocardial infarction and myocyte necrosis respectively were: serial ECG / ST
segment monitoring 33% and 23%; CK-MB(mass) 96% and 63%; troponin T (using 0.03 ng/ml
threshold) 96% and 90%. The only test that added useful prognostic information was exercise
treadmill testing (relative risk 6 for cardiac death, non-fatal myocardial infarction or arrhythmia
over six months).
Conclusion:  Serial ECG / ST monitoring, as used in our protocol, adds little diagnostic or
prognostic value in patients with a normal or non-diagnostic initial ECG. CK-MB(mass) can rule out
ACS with clinical myocardial infarction but not myocyte necrosis(defined as a troponin elevation
without myocardial infarction). Using a low threshold for positivity for troponin T improves
sensitivity of this test for myocardial infarction and myocardial necrosis. Exercise treadmill testing
predicts subsequent adverse cardiac events.
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Background
The chest pain unit (CPU) has been developed to provide
standardised care for patients presenting with acute chest
pain, undiagnosed by initial clinical assessment, electro-
cardiogram (ECG) and chest radiograph. The CPU aims to
rapidly diagnose acute coronary syndrome (ACS), provid-
ing early access to appropriate care for those with positive
test results and discharge home for those who test nega-
tive. Although a variety of different tests have been used in
CPU protocols, most units use a combination of ECG
monitoring, biochemical diagnostic testing and provoca-
tive cardiac testing to diagnose ACS [1]. This has led to
some debate regarding the most appropriate testing
regime. In particular, the role of the exercise treadmill test
has been questioned [2] and does not feature in some pro-
tocols [3].
Since 1999 a CPU has been operating at the Northern
General Hospital in Sheffield. Patients are investigated
with a combination of serial ECG recording, ST segment
monitoring, biochemical cardiac markers (CK-MB(mass)
and troponin T) and an exercise treadmill test [4]. We
aimed to determine the value of each of the constituent
elements of this protocol by measuring: a) the diagnostic
accuracy (sensitivity, specificity and likelihood ratios) of
each test for ACS at presentation, and b) prognostic value
of each test for major adverse cardiac events over six
months.
Methods
The Northern General Hospital is a 1100-bedded urban
teaching hospital with the only adult emergency depart-
ment for the 530,000 population of Sheffield, United
Kingdom. The emergency department see approximately
90,000 new patients per year, of whom approximately 6%
have chest pain. The hospital is a tertiary referral centre for
cardiology, with cardiac catheterisation and cardiac sur-
gery facilities. The CPU is a two-bedded, nurse-run unit
based in the emergency department. Patients are assessed
on the unit if they present with acute chest pain and have
a normal or non-diagnostic ECG, no co-morbidity requir-
ing admission, no serious alternative cause for chest pain
(such as pulmonary embolus) and pain that is potentially
compatible with cardiac ischaemia (i.e. not chest wall
pain). Patients with known coronary heart disease can be
assessed on the CPU provided they do not have prolonged
(> one hour) or recurrent (more than one episode) pain
that is characteristic of their angina.
The diagnostic testing regime consists of ST segment mon-
itoring and serial ECG recording every hour for two to six
hours; CK-MB(mass) assay on arrival, repeated either two
hours later or six hours after symptom onset, whichever is
later; troponin T assay at least six hours after symptom
onset; and, if appropriate, exercise treadmill testing. Exer-
cise testing is not performed if any preceding test is posi-
tive, if the patient has had recent diagnostic testing for
coronary heart disease (e.g. coronary angiography), or if
they are unable to exercise.
From 1/3/99 to 30/9/00 presenting details, CPU processes
and diagnostic test results were prospectively recorded for
all patients assessed on the CPU. Patients admitted after
assessment received further testing and management at
the discretion of the admitting physician and were fol-
lowed up by case note review. Patients discharged after
assessment were invited to attend a review appointment
on the CPU 72 hours later for clinical assessment, ECG
and troponin T measurement.
Six months after assessment the emergency department
computer database was searched for details of any further
hospital attendances or admissions. Case notes were
reviewed for all cases identified. The general practitioners
of all patients presenting between 1/3/99 and 29/2/00
were contacted by post to determine if they had suffered
any adverse cardiac event or received diagnostic cardiac
testing or procedures during the previous six months. This
survey revealed no previously unidentified episodes so for
patients attending from 1/3/00 to 30/9/00 the general
practitioner was only contacted if the patient resided out-
side the Sheffield area. We did not attempt to contact
patients at six months to confirm whether they were still
alive.
ST segment monitoring and serial ECG recording was per-
formed using Spacelabs monitors. These functions will be
evaluated together, because: 1) serial ECG recording is
facilitated and influenced by the availability of this mon-
itoring equipment, and 2) ECG changes detected on ST
segment monitoring may also be detected on serial
recording and vice-versa. Each patient received between
two and six hours of ST segment monitoring and at least
two ECGs, one hour apart. Results were dichotomised
into positive (>1 mm ST segment elevation or depression;
T wave inversion > 2 mm or normalisation; ventricular
arrhythmia; or second or third degree heart block) or neg-
ative (none of these changes). ECGs were interpreted by
the specialist chest pain nurses who managed the unit.
Table 1: Characteristics of the study population
Mean age 53.6 years (range 22 to 99)
Male 431 (61%)
Known coronary heart disease 150 (21%)
Diabetes 48 (7%)
Hypertension 181 (26%)
Hyperlipidaemia 114 (16%)
Smoker 215 (35%)BMC Emergency Medicine 2005, 5:6 http://www.biomedcentral.com/1471-227X/5/6
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Positive changes were defined a priori and used for CPU
decision-making.
The absolute value of CK-MB(mass) at baseline and on
repeat sampling was defined as positive if it exceeded 5
ng/ml. The rise in CK-MB(mass) (delta CK-MB(mass))
was defined as positive if it exceeded 1.6 ng/ml. The diag-
nostic performance of baseline, repeat assay and change
in CK-MB(mass) were analysed separately and then com-
bined to give an overall result. This was defined as positive
if either assay or the change were positive, and negative if
all three results were negative. Two thresholds for positiv-
ity were analysed for troponin T: 1) the traditional thresh-
old of 0.1 ng/ml or above, and 2) a more sensitive
threshold of 0.03 ng/l. The CK-MB(mass) thresholds and
the 0.1 ng/ml threshold for troponin were defined a priori
and used for decision making on the CPU. The 0.03 ng/ml
troponin threshold was only used for post hoc analysis.
The exercise treadmill test was performed according to the
Bruce protocol. A positive test was defined as more than 1
mm horizontal or down-sloping ST segment depression;
more than 1 mm ST elevation; or ventricular arrhythmia.
For the purposes of this analysis, any test that did not pro-
duce these changes was considered to be negative, regard-
less of the duration of exercise or heart rate achieved.
The diagnostic performance of all tests except the exercise
treadmill test was evaluated by comparison to the refer-
ence standard diagnosis of ACS at presentation, catego-
rised as recently recommended [5] into: 1) ACS with
clinical myocardial infarction (defined as a typical clinical
syndrome associated with a troponin T elevation greater
than 1.0 ng/ml), or 2) ACS with myocyte necrosis
(defined as a typical clinical syndrome with any detecta-
ble troponin T less than 1.0 ng/ml). Sensitivity, specificity,
positive and negative predictive values, and likelihood
ratios were calculated for each test, along with 95% confi-
dence intervals.
The prognostic value of each test was evaluated by meas-
uring the relative risk of a major adverse cardiac event dur-
ing the six months following a positive result, compared
to a negative result. The following were defined as major
adverse cardiac events: cardiac death, non-fatal myocar-
dial infarction, arrhythmia, or revascularisation proce-
dure. Because revascularisation procedures may be
precipitated by the diagnostic tests under investigation,
we repeated the analysis with these excluded from the
definition.
Data were analysed using SPSS for windows version 11.5
(SPSS Inc., Chicago) and 95% confidence intervals for all
proportions, likelihood ratios and risk ratios were calcu-
lated using CIA, Confidence Interval Analysis software.
The North Sheffield Research Ethics Committee approved
the evaluation of the chest pain unit.
Results
During the study period 706 patients were assessed on the
CPU. Details of the study population characteristics are
outlined in table 1. All patients received baseline blood
sampling. This was performed at a mean time from symp-
tom onset of 6.2 hours (median 3.0 hours). Repeat blood
sampling was performed on 604 patients (86%) at a mean
time from symptom onset of 8.6 hours (median 6.5
hours). After CPU assessment 596 (84%) were discharged
home and 110 (16%) were admitted. Of those discharged,
515 (86%) returned for review at 72 hours. At review one
patient had a previously undetected rise in troponin T (0.8
ng/ml) and was classified as having ACS with myocyte
necrosis. All other cases of ACS were detected by the CPU
protocol.
ACS with clinical myocardial infarction was ultimately in
diagnosed in 30 patients (4.2%), while another 30 (4.2%)
had ACS with myocyte necrosis. Over the following six
months 32 patients (4.5%) had a major adverse cardiac
event. These included eight cardiac deaths, five non-fatal
myocardial infarctions, two arrhythmias, and 17 revascu-
larisation procedures.
Table 2: Sensitivity, specificity, positive and negative predictive values for the diagnosis of ACS with clinical myocardial infarction at 
presentation
Sensitivity (95% CI) Specificity (95% CI) Positive predictive 
value (95% CI)
Negative predictive 
value (95% CI)
Serial ECG & ST monitoring N = 690 33.3% (19.2 to 51.2) 95.3% (93.4 to 96.7) 24.4% (13.8 to 39.3) 96.9% (95.3 to 98.0)
Initial CK-MB(mass) N = 687 63.3% (45.5 to 78.1) 97.0% (95.3 to 98.0) 48.7% (33.9 to 63.8) 98.3% (97.0 to 99.0)
Delayed CK-MB(mass) N = 601 95.7% (79.0 to 99.2) 96.2% (94.3 to 97.5) 50.0% (35.8 to 64.2) 99.8% (99.0 to 100)
Delta CK-MB(mass) N = 601 95.7% (79.0 to 99.2) 98.4% (97.0 to 99.1) 70.0% (53.4 to 83.9) 99.8% (99.0 to 100)
Any positive CK-MB(mass) N = 601 100% (88.6 to 100) 95.6% (93.7 to 96.9) 50.8% (38.3 to 63.2) 100% (99.4 to 100)
Troponin T > = 0.1 ng/ml N = 686 83.3% (66.4 to 92.7) 98.8% (97.7 to 99.4) 75.8% (59.0 to 87.2) 99.3% (98.3 to 99.7)
Troponin T > = 0.03 ng/ml N = 686 96.4% (82.3 to 99.4) 95.9% (94.1 to 97.2) 50.0% (37.1 to 62.9) 99.8% (99.1 to 100)BMC Emergency Medicine 2005, 5:6 http://www.biomedcentral.com/1471-227X/5/6
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Serial ECG/ST segment monitoring was performed for
690 patients, baseline CK-MB(mass) was measured in
687, repeat CK-MB(mass) was measured in 601, troponin
T was measured in 686 patients, and 422 patients received
an exercise treadmill test. Table 2 shows the sensitivity,
specificity, positive and negative predictive values and
table 3 shows the likelihood ratios of the tests for ACS
with clinical myocardial infarction at presentation. The
same parameters are outlined for ACS with clinical myo-
cardial infarction or myocyte necrosis in tables 4 and 5.
Serial ECG / ST segment monitoring added relatively little
to the assessment. None of the positive cases involved ST
elevation myocardial infarction requiring reperfusion
therapy. All the biochemical markers were useful for rul-
ing in ACS with clinical myocardial infarction and ACS
with myocyte necrosis. The second CK-MB(mass) sample
and the delta CK-MB(mass) were useful for ruling out
myocardial infarction, but did not reliably rule out myo-
cyte necrosis. Using a lower threshold for troponin T pos-
itivity markedly improved sensitivity with only a modest
loss of specificity. Only troponin T, using a lower thresh-
old, was useful for ruling out ACS with myocyte necrosis.
However, it should be recognised that this diagnosis is
based upon detection of troponin T.
Table 6 shows the relative risk of all cardiac events over the
subsequent six months for each diagnostic test and table
7 shows the relative risk of cardiac death, non-fatal AMI or
Table 3: Likelihood ratios for the diagnosis of ACS with clinical myocardial infarction at presentation
Positive likelihood ratio (95% CI) Negative likelihood ratio (95% CI)
Serial ECG & ST monitoring N = 690 7.1 (3.8 to 13.1) 0.700 (0.543 to 0.901)
Initial CK-MB(mass) N = 687 20.8 (12.5 to 34.7) 0.378 (0.236 to 0.605)
Delayed CK-MB(mass) N = 601 25.1 (16.5 to 38.2) 0.045 (0.007 to 0.307)
Delta CK-MB(mass) N = 601 61.4 (39.1 to 118.1) 0.044 (0.006 to 0.300)
Any positive CK-MB(mass) N = 601 ~25* ~0*
Troponin T > = 0.1 ng/ml N = 686 70.4 (34.1 to 140.8) 0.169 (0.079 to 0.387)
Troponin T > = 0.03 ng/ml N = 686 23.5 (16.1 to 34.2) 0.037 (0.005 to 0.255)
*Unable to calculate precisely as no false negative were recorded
Table 4: Sensitivity, specificity, positive and negative predictive values for the diagnosis of ACS with myocyte necrosis or clinical 
myocardial infarction at presentation
Sensitivity (95% CI) Specificity (95% CI) Positive predictive value 
(95% CI)
Negative predictive value 
(95% CI)
Serial ECG & ST monitoring N = 690 23.3% (14.4 to 35.4) 95.7% (93.8 to 97.0) 34.1% (21.6 to 49.5) 92.9% (90.7 to 94.6)
Initial CK-MB(mass) N = 687 43.3% (31.6 to 55.9) 97.9% (96.5 to 98.8) 66.7% (51.0 to 79.4) 94.8% (92.8 to 96.2)
Delayed CK-MB(mass) N = 601 63.5% (49.9 to 75.2) 98.0% (96.4 to 98.9) 75.0% (60.6 to 85.4) 96.6% (94.7 to 97.8)
Delta CK-MB(mass) N = 601 55.8% (42.3 to 68.4) 99.6% (98.7 to 99.9) 93.5% (79.3 to 98.2) 96.0% (94.0 to 97.3)
Any positive CK-MB(mass) N = 601 71.7% (59.2 to 81.5) 97.4% (95.9 to 98.4) 72.9% (60.4 to 82.6) 97.3% (95.7 to 98.3)
Troponin T > = 0.1 ng/ml N = 686 55.0% (42.5 to 66.9) 100% (99.4 to 100) 100% (89.6 to 100) 96.0% (94.2 to 97.2)
Troponin T > = 0.03 ng/ml N = 686 89.7% (79.2 to 95.2) 99.7% (98.8 to 99.9) 96.3% (87.5 to 99.0) 99.6% (97.9 to 99.9)
Table 5: Likelihood ratios for the diagnosis of ACS with myocyte necrosis or clinical myocardial infarction at presentation
Positive likelihood ratio (95% CI) Negative likelihood ratio (95% CI)
Serial ECG & ST monitoring N = 690 5.4 (3.0 to 9.8) 0.801 (0.696 to 0.922)
Initial CK-MB(mass) N = 687 20.9 (11.3 to 38.5) 0.579 (0.464 to 0.722)
Delayed CK-MB(mass) N = 601 31.7 (17.0 to 58.9) 0.373 (0.261 to 0.534)
Delta CK-MB(mass) N = 601 153.1 (37.6 to 623.5) 0.444 (0.327 to 0.602)
Any positive CK-MB(mass) N = 601 28.1 (16.9 to 46.7) 0.291 (0.194 to 0.435)
Troponin T > = 0.1 ng/ml N = 686 ~25* ~0*
Troponin T > = 0.03 ng/ml N = 686 281.5 (70.4 to 1126) 0.104 (0.049 to 0.221)
*Unable to calculate precisely as no false positives were recordedBMC Emergency Medicine 2005, 5:6 http://www.biomedcentral.com/1471-227X/5/6
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arrhythmia. Positive results for serial ECG / ST segment
monitoring or biochemical cardiac markers showed a
weak association with cardiac events over the following
six months. This association disappeared when revascu-
larisation procedures were excluded from the definition of
cardiac events. Positive exercise stress test result showed a
much stronger association with cardiac events, which was
maintained even when revascularisation procedures were
excluded.
Discussion
These findings suggest that serial ECG recording and ST
segment monitoring, as applied in our protocol, add little
diagnostic value in patients with a normal or non-diag-
nostic initial ECG. Only a minority of cases of ACS were
detected by ECG monitoring and most of the positive
results from this test were false positives. Serial ECG
recording and ST segment monitoring offers the potential
advantage of allowing early detection of ST segment eleva-
tion myocardial infarction that may be eligible for throm-
bolysis [6], but no such cases occurred in our cohort. Our
findings are consistent with those of Decker et al [7] who
found that serial ECG was of limited value in their CPU
protocol. It should be appreciated, however, that our
protocol used a variable duration of ST segment monitor-
ing and a variable number of serial ECGs, with some
patients receiving only two hours of monitoring and two
serial ECGs. Hence these findings may not apply to more
prolonged regimes, or to populations with a higher prev-
alence of ACS.
Baseline CK-MB(mass) testing allows early detection of
ACS and calculation of a CK-MB(mass) rise. However, the
initial CK-MB(mass) alone has insufficient sensitivity to
rule out ACS. The addition of a repeat sample at least two
hours later and at least six hours after the onset of pain
provides adequate sensitivity to rule out ACS with
myocardial infarction, but not myocyte necrosis. Our esti-
mate of sensitivity for myocardial infarction is consistent
with previously published estimates [3,8,9]. If we simply
wish to rule out myocardial infarction then this would
appear to be a relatively cheap and effective way of achiev-
ing that aim.
Using a traditional threshold for positivity of 0.1 ng/ml
for troponin T [10,11] in this protocol does not reliably
rule out myocardial infarction or myocyte necrosis. How-
ever, if a lower threshold of 0.03 ng/ml is used then 96%
Table 6: Relative risk of a cardiac event over the following six months
Test Event rate:
positive test
Event rate:
negative test
Relative risk (95% CI)
Serial ECG & ST monitoring N = 690 5/41 27/649 2.72 (1.10 to 6.74)
Initial CK-MB(mass) N = 687 5/39 27/648 2.84 (1.15 to 7.02)
Delayed CK-MB(mass) N = 601 5/44 23/557 2.57 (1.02 to 6.47)
Delta CK-MB(mass) N = 601 3/31 25/570 2.10 (0.67 to 6.61)
Any positive CK-MB(mass) N = 601 8/59 24/628 3.24 (1.52 to 6.93)
Troponin T > = 0.1 ng/ml N = 686 8/33 24/673 6.80 (3.31 to 13.96)
Troponin T > = 0.03 ng/ml N = 686 9/54 23/632 4.58 (2.23 to 9.40)
Exercise treadmill test N = 422 9/37 4/385 19.03 (6.10 to 59.34)
Table 7: Relative risk of cardiac death, non-fatal myocardial infarction or arrhythmia over the following six months
Test Event rate: 
positive test
Event rate: 
negative test
Relative risk
Serial ECG & ST monitoring N = 690 1/41 15/649 1.06 (0.14 to 7.79)
Initial CK-MB(mass) N = 687 0/39 16/648 -
Delayed CK-MB(mass) N = 601 1/44 13/557 0.97 (0.13 to 7.28)
Delta CK-MB(mass) N = 601 0/31 14/570 -
Any positive CK-MB(mass) N = 601 1/59 15/628 0.71 (0.09 to 5.28)
Troponin T > = 0.1 ng/ml N = 686 1/33 15/673 1.36 (0.18 to 9.98)
Troponin T > = 0.03 ng/ml N = 686 2/54 14/632 1.67 (0.39 to 7.17)
Exercise treadmill test N = 422 2/37 3/385 6.63 (1.14 to 38.50)BMC Emergency Medicine 2005, 5:6 http://www.biomedcentral.com/1471-227X/5/6
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of cases of myocardial infarction and almost 90% of cases
of myocyte necrosis will be detected. This finding is con-
sistent with previously published data showing that use of
a lower threshold for positivity for troponin T is associ-
ated with improved early sensitivity [12]. However, since
we tested this threshold as a post hoc analysis, further pro-
spective validation of the performance of a lower thresh-
old is required. Furthermore, lowering the threshold
would be expected to reduce specificity and lead to more
false positives being generated. Potential incorporation
bias (see limitations section) means that it is difficult to
determine the impact of altering the threshold upon
specificity.
The question of whether to use CK-MB(mass) or troponin
T or both is a subjective judgement in which the benefits
of detecting and treating cases of ACS must be weighed
against the costs of additional testing and management of
false positives. ACS with myocardial infarction is associ-
ated with a markedly increased risk of adverse
events[5,10] and thus an increased expectation of benefit
from treatment [13]. The risks of ACS with myocyte necro-
sis are smaller, but still indicate potential benefit from
detection and treatment [5]. In estimating the potential
costs and benefits of detecting cases of ACS we also need
to consider prevalence. CPU patients have a low
prevalence of ACS, so a large number of additional
patients will need to be tested to detect a small number of
additional cases.
The value of exercise treadmill testing in a CPU protocol
has been questioned [2]. It may be costly to implement
and risks generating large number of false positives due to
poor specificity. This study has shown that exercise tread-
mill testing offers useful prognostic information that is
not provided by ECG or biochemical testing. Meanwhile,
concerns about false positives are undermined by evi-
dence from a recent randomised controlled trial [14] in
which two-thirds of patients randomised to CPU care
received an exercise treadmill test compared to only one-
third of the routine care group. Despite this difference the
rate of referral for angiography was identical. Whether the
additional prognostic information provided by treadmill
testing justifies the addition cost remains debatable.
This study has a number of limitations that should be
appreciated. The reference standard for diagnosis was not
independent of the tests being evaluated. Troponin eleva-
tion was the diagnostic criterion for ACS so estimates of
sensitivity and particularly specificity will be subject to
incorporation bias. Any patient who has an elevated
troponin will, by definition, have a diagnosis of ACS,
unless repeat sampling shortly afterwards is negative.
Therefore specificity of troponin, using this definition of
ACS, is expected to be high. The value of our analysis of
troponin therefore lies in assessment of early sensitivity,
particularly in comparing the early sensitivity of using dif-
ferent thresholds for positivity.
Caregivers were aware of the results of all the tests under
evaluation and thus would be more likely to rigorously
follow-up those with positive tests, raising the possibility
of work-up bias. Patients with positive tests were admitted
while those with negative tests were discharged. Although
86% of discharged patients attended review at 72 hours, it
is possible that some patients with false negative initial
tests may have failed to attend follow-up, and were thus
misclassified as true negative. A similar bias may influence
the association between test results and adverse events
when revascularisation procedures are included in the def-
inition, but not the association between treadmill testing
and adverse events limited to cardiac death, non-fatal
myocardial infarction or arrhythmia.
Statistical analysis inevitably requires some simplification
of the data used. For ST segment monitoring / serial ECG
and for exercise treadmill testing this involved categoris-
ing all results into positive or negative. For exercise tread-
mill testing inconclusive results were classified as
negative. This approach may lead to under-estimation of
the diagnostic value of the tests. Furthermore, since
patients with new abnormalities on their ECG were
excluded from CPU evaluation, it is perhaps not surpris-
ing that further ECG-based tests had limited value. This
again reinforces the importance of not extrapolating these
findings to different populations, such as those with a
high prevalence of ACS.
Conclusion
ST segment monitoring and serial ECG recording, as
applied in our protocol, appears to add little diagnostic
value in patients with a normal or non-diagnostic initial
ECG. CK-MB(mass) measurement allows reliable detec-
tion of ACS with myocardial infarction but not myocyte
necrosis (defined as a troponin elevation without myocar-
dial infarction). Using a low threshold for positivity for
troponin T improves sensitivity of this test for myocardial
infarction. Exercise treadmill testing offers additional
prognostic information regarding the risk of subsequent
adverse cardiac events.
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